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MiR-134 has been reported to have a role in the development and progression of various cancers. In
this study, we found that miR-134 expression was significantly decreased in chemo-resistant serous
epithelial ovarian cancer (EOC) patients. Over-expression of miR-134 enhanced the sensitivity of
SKOV3-TR30 cells to paclitaxel, and increased paclitaxel-induced apoptosis. Further, Pak2 was iden-
tified as a direct target of miR-134, and Pak2-specific siRNA increased cell inhibition rate and pro-
moted paclitaxal-induced apoptosis. By regulating Pak2 expression, miR-134 could mediate Bad
phosphorylation at Ser112 and Ser136, which affected cell survival and apoptosis. In conclusion,
our findings indicate that repression of miR-134 and consequent up-regulation of Pak2 might con-
tribute to paclitaxel resistance.
 2015 Published by Elsevier B.V. on behalf of the Federation of European Biochemical Societies.1. Introduction
The incidence rate of ovarian cancer in the female population
accounts for the second most common tumor and is ranked the
number one cause of mortality [1]. At present, the international
recommended treatment guideline or gold standard is surgery that
is supplemented by paclitaxel and platinum based chemotherapy.
However, most patients will relapse in one to 2 years and the
5-year survival rate is still low (30%) due to chemoresistance [2].
Therefore, searching for the molecular basis of chemoresistance
is ongoing.
The MicroRNA (MiRNA) are 21–25 nucleotides small non-
coding RNAs. In mammalian cells, miRNAs play a significant role
in regulating gene expression at both transcriptions and at post-
transcriptional level [3]. These transcripts are crucial regulators
of fundamental cellular functions, including proliferation, apopto-
sis, invasion and differentiation [4,5]. Recently, several studies
have shown that miRNA played an important role in chemo resis-
tance of ovarian cancer. Mir-199b-5p is associated with acquiredchemo resistance in ovarian cancer [6] and miR-93 contributes to
cisplatin chemo sensitivity in ovarian cancer cells by regulating
PTEN/Akt pathway [7]. Additionally, miR-29b and its signaling
mechanism involved in patients with ovarian cancer [8]. The inhi-
bition of miR-21 promotes apoptosis and, thus causes drug sensi-
tivity in ovarian cancer [9]. The miR-197 contributes to paclitaxel
resistance in ovarian cancer cells [10]. Huh [11] in their study
found that dysregulation of miR-106a and miR-591 leads to pacli-
taxel resistance in ovarian cancer. Cittelly [12] discovered that
restoration of miR-200c in ovarian cancer increased sensitivity to
paclitaxel. MiR-134 has been reported to show down-regulation
in multi-resistant small cell lung cancer and esophageal cancers
[13–16]. Hirota found that miR-134 in lung cancer tissue decreased
significantly; by inhibiting dihydro pyrimidine dehydrogenase
(DPD) protein expression affects 5-fluorouracil sensitivity in lung
cancer [15]. Kitamura et al. in their study found that miR-134 par-
ticipates in TGF-b induced transformation of epithelial mesenchy-
mal by regulating MAGI2 and causes gefitinib resistance in lung
adenocarcinoma cancer cells [16]. However, the role of miR-134
in paclitaxel resistance of ovarian cancer is still relatively
unknown.
In this study, we aim to search the significance of decreased
expression of miR-134 in serous epithelial ovarian carcinoma and
clarify that miR-134 by regulating Pak2 expression might con-
tribute to paclitaxel resistance. In our study, we performed
microarray analysis and found miR-134 was decreased in serous
epithelial ovarian carcinoma chemo-resistant tissues. We further
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effectors which might directly execute function of decreased
expression of miR-134 in ovarian cancer paclitaxel resistance.
Our study for the first time speculated that miR-134 regulating
Pak2 expression contributes to ovarian cancer cell sensitivity
maybe through Bad phosphorylation at Ser112 and Ser136.
2. Materials and methods
2.1. Tissue samples
Ovarian cancer tissue samples were obtained from routine sur-
gery at Shengjing Hospital of China Medical University between
2010 and 2012 from female patients who received platinum-
paclitaxel therapy after surgery. All patients were not pretreated
with radiotherapy or chemotherapy prior to surgery. Patients with
progressive disease during primary chemotherapy or those who
suffered a recurrent disease within 6 months of completing pri-
mary chemotherapy were labeled as drug resistant (total of 24).
Patients who had recurrences beyond 6 months or with no recur-
rence were drug sensitive (total of 24). All the samples selected
were serous EOC (seen in Supplemental Tables 1 and 2). Samples
were immediately frozen and stored in liquid nitrogen for analysis.
The research study was reviewed by our ethics committee, and the
study was approved by the institutional review board of Shengjing
Hospital of China Medical University. Informed consent was
obtained from all the female patients.
2.2. Cell culture
The ovarian carcinoma cell line SKOV3 was provided by Tumor
Cell Bank Research Institute of the Chinese Academy of Medical
Sciences (Beijing, China). The paclitaxel-resistant ovarian carci-
noma cell line, SKOV3-TR30 cells was derived from SKOV3 cell line
and provided by Zhejiang University affiliated Obstetrics and
Gynecology Hospital (Hangzhou, China). SKOV3, SKOV3-TR30 cells
were grown in RPMI 1640 medium (Hyclone, Logan, UT, USA) sup-
plemented with 10% fetal bovine serum (Gibco Life Technologies,
Grand Island, NY, USA) and 1% penicillin/streptomycin (Hyclone,
Logan, UT, USA). SKOV3-TR30 cells were maintained with the addi-
tion of 30 nmol/L of paclitaxel (Sigma Aldrich, St. Louis, MO). Pacli-
taxel was withdrawn a week before the experiment. All cells were
maintained in a humidified atmosphere containing 5% CO2 at 37 C.
Cells in the logarithmic phase of growth were used for all studies
described.
2.3. MicroRNA gene chip
Total RNA were extracted from 60 mg of frozen tumor tissues
using Trizol (Invitrogen, Carlsbad, CA). We analyzed the expression
profiles of miRNA on 4 pairs of the chemo-sensitive and chemo-
resistant serous EOC tissue samples using FlashTagTM Biotin RNA
Labeling Kit for Affymetrix GeneChipmiRNA Arrays (Genisphere,
FT30AFYB) (CaptialBio Corporation). The Cluster 3.0 software was
used for the analysis of microRNA expression. The criteria for dif-
ferentially expressed miRNA is |Score (d)|P 2, and fold change
P2 or 60.5.
2.4. Plasmid generation
As acquired from previous hybrid PCR method [17], we found
one potential binding site for miR-134 in the CDS (coding
sequence) region of Pak2 gene (The coding region of a gene, also
known as the coding sequence or CDS, is that portion of a gene’sRNA, composed of exons, that codes for protein). We designed one
pair of primers for cloning the fragment containing the potential
binding sites of miR-134 (Primers used for the fragment containing
were as following: Sense 50 GGACTAGT ATG TCT GAT AAC GGA GAA
CTG GAAG 30, Antisense: 50 CCCAAGCTT TCT CCA GTA ACA GCA
TCAA 30). The PCR products were then digested with Spe I and Hin-
dIII, followed by insertion into Spe I and, HindIII digested the
pMIR-Report vector (Ambion, Carlsbad, CA) to obtain a luciferase
construct. Then site-directed gene mutagenesis kit (ThermoFisher
Scientific, Waltham, MA, USA) was applied to create the mutant
counterpart, by using the mutant primers (the sequence were as
following: Sense 50 AGACCCTTTGTCAGCATACACGAGTTT
GAAACCTTTGCC 30, Antisense 50 GGCAAAGGTTTCAAACTCGTG
TATGCTGACAAAGGGTCT 30). Pak2 gene over-expression plasmid
was constructed into a pBI plasmid (Clonetech). To be specific,
the complete CDS region was cloned with primer: Sense 50
CGACGCGT ATGTCTGATAACGGAGAACTGGAAG 30; Antisense 50
ACGCGTCGAC ACGGTTACTCTTCATTGCTTCTTTA 30. The PCR pro-
duct was digested with Mlu, Sal, and then inserted into pBI plasmid
to obtain Pak2 over-expression plasmid named as
pBI-Pak2.
2.5. RNA isolation and quantitative reverse transcriptase PCR
Total RNA was isolated using Trizol agent (Invitrogen, Carlsbad,
CA) and treated by TURBO DNA-freeTM Kit (Ambion, Carlsbad, CA)
according to the manufacturer’s instructions. For miR-134 quanti-
tative real-time reverse transcriptase-polymerase chain reaction
(qRT-PCR), cDNA was synthesized from 10 ng of total RNA using
TaqManTM miRNA hsa-miR-134 specific primers (Applied Biosys-
tems Life Technologies, Beijing, China) and a TaqManTM MicroRNA
Reverse Transcription Kit (Applied Biosystems Life Technologies).
The qPCR was performed on the ABI PRISM 7300 Sequence Detec-
tion System (Applied Biosystems Life Technologies) and the U6
snRNA was used as an endogenous control and, fold change of
expression was calculated according to the 2DDCT methods. All
reactions were performed in triplicate.
For Pak2 mRNA expression, cDNA was generated using the Pri-
meScriptVR RT reagent Kit (Takara, Dalian, China). A quantitative
real-time polymerase chain reaction (qRT-PCR) assay was per-
formed to evaluate mRNA expression using the SYBR Select Mas-
ter Mix (Applied Biosystems Life Technologies) on the ABI PRISM
7300 Sequence Detection System (Applied Biosystems Life Tech-
nologies) Primer of Pak2 was design as Sense: TGGTCGGAACGCCA-
TACTG, Antisense: TTCTGGGGTTCCATTAGTTGC (actin, Sense:
CTCCATCCTGGCCTCGCTGT, Antisense: GCTGTCACCTTCACCGTTCC).
The relative expression levels of each sample were measured using
2DDCT methods. All reactions were performed in triplicate.
2.6. Luciferase activity assay
Ovarian cancer paclitaxel resistance SKOV3-TR30 cells were
applied for the luciferase activity assays. Cells were plated at
2  105 cells per well in a 24-well plate 24 h before transfection.
Cells were transfected with luciferase reporter constructs
(400 ng) and, miR-134 mimics (100 nM) with Lipofectamine 3000
(Invitrogen) according to the manufacturer’s protocol. The
pRL-TK vector (promega, Madison, WI, USA) was co-transfected
as an internal control to correct the differences in both transfection
and harvest efficiencies. After 24 h cell lysate was prepared by
using Dual-Luciferase Reporter Assay Kit (Promega) and lucifer-
ase activity was analyzed using the Dual-Luciferase Reporter Assay
System (Promega). Transfected wells were analyzed in triplicate
for each group.
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MiR-134 mimic, miR-134 inhibitor and miRNA mimic negative
control (miRNA-mimic NC) or miRNA inhibitor negative control
(miRNA-inhibitor NC)were chemically synthesized by RIBOBIO
(Guangzhou, China). RNA oligonucleotides were transfected into
cells at a final concentration of 100 nM using Lipofectamine 3000
(Invitrogen) according to the manufacturer’s protocol. Pak2 siRNA
product was designed and synthesized by Ambion (siRNA ID
s10023, Sense 50 GGUGAUGAAAGAAUUGAAAtt 30, Antisense 50
UUUCAAUUCUUUCAUCACCag 30, siRNA ID s10024, Sense 50
CAGAGGUGGUUACACGGAAtt 30, Antisense 50 UUCCGUGUAACCAC-
CUCUGgt 30). SiRNA of Pak2 was transfected into cells at a final
concentration of 50 nM using Lipofectamine 3000 (Invitrogen)
according to the manufacturer’s protocol.
2.8. CCK-8 assay
SKOV3-TR30 cells were plated in 96-well plates at 5  103 cells
per well. Paclitaxel (sigma) was prepared freshly at various con-
centrations and, then added. The cells were incubated for 48 h. Cell
viability was assessed using the CCK-8 assay (DOJINDO, Kuma-
moto, Japan), and, the half maximal inhibitory concentration
(IC50) was calculated. The absorbance of each well at the wave-
length of 450 nm was read on a spectrophotometer (XFLUOR4
Version: V 4.51). At least three independent experiments were
performed in quadruplicate.
2.9. Cell apoptosis assay
Cells were plated at a density of 2  105 cells/2 ml medium in 6
well plates 24 h. After seeding, SKOV3-TR30 cells were transfected
with miR-134 mimic (miRNA mimic NC) or siRNA of Pak2 (siRNA
negative control). After 48 h of transfection, SKOV3-TR30 cells
were then treated with 200 nmol/L paclitaxel. After 24 h of treat-
ment, cells were harvested and washed twice in PBS for cell apop-
tosis. Cell apoptosis was detected by using Annexin V-FITC
Apoptosis Detection Kit (BD Pharmingen, Mountain view, CA, US)
according to the manufacture’s instruction. Cells were stained with
Annexin V and PI in the binding buffer for 30 min in the dark and
then analyzed through flow cytometry (BD FACSAriaTM Fusion).
2.10. Western blotting
Protein were harvested using RIPA lysis buffer (ThermoFisher
Scientific), diluted with a buffer containing SDS (Life Technologies),
and, denatured at 95 C for 10 min. Proteins (20 lg) were elec-
trophoresed on 10% SDS–polyacrylamide gels and transferred to
PDVFmembranes. Membranes were washed with Tris buffered sal-
ine (TBS, Sigma Aldrich, St. Louis, MO, USA), blocked with 5% dried
non-fat milk (Bio-Rad Laboratories, Hercules, CA, USA) in 1%
Tween–TBS and probed with antibody raised against Pak2 (Abcam,
Cambridge, UK, 1:500), Bad (Abcam, 1:500), phospho-Bad (Ser112,
Ser136) (CST, MA, USA, 1:1000) with GAPDH (Abcam, 1:2000) as a
visual loading control. Bands were visualized by secondary anti-
body IgG-linked horseradish peroxidase conjugate (1:2000) with
ECL and were quantified using Chemi-Doc XRS imaging software
(Bio-Rad).
2.11. Statistical analysis
All values were expressed as mean ± SD. Statistical comparison
among different groups was performed using Student’s t-test.
Receiver operating characteristic (ROC) curve, which was gener-
ated by calculating the sensitivities and specificities at the cutoff-
point was applied to determine the diagnostic significance ofmiR-134 expression to ovarian cancer chemo resistance. All statis-
tical analyses were performed using SPSS17.0 statistical software.
The difference was considered to be significant when the P value
was <0.05.3. Results
3.1. Downregulation of miR-134 in chemo-resistant serous EOC tissues
In this study, we compared the miRNA expression profile
between 4 cases of chemo sensitive and 4 cases of chemo-
resistant serous EOC tissue samples by applying miRNA microar-
ray. SAM (significance analysis of microarrays) was applied to
identify the differentially expressed miRNAs. MiRNAs were consid-
ered significantly altered only when they fulfilled the following cri-
teria (1) mean fold changeP2 or 60.5. (2) SAM score >2 or <-2. In
our study, we found three differentially expressed miRNAs.
MiR-210 and miR-1307 were positive genes (shown in Fig. 1A in
red) while miR-134 was negative genes (shown in Fig. 1A in green).
Which means miR-1307 and miR-210 were the significantly
increased miRNAs, whereas miR-134 was detected significantly
decreased in ovarian cancer chemo-resistant tissues (the
score = 2.19827, the fold change = 0.4289 which fulfilled the
criteria mentioned above). Other miRNAs were not differentially
expressed (Shown in Fig. 1A in black). We selected miR-134
because it was the only miRNA showed decreased expression.
We further used qPCR to analyze the expression level of miR-134
in another 20 pairs of tissue samples taken from 20 cases of ovar-
ian cancer chemo-resistant patients and 20 cases of patients who
appeared sensitive to chemotherapy. Results showed the
expression level of miR-134 was significantly decreased in
chemo-resistant tissue samples. To be specific, we normalized
the expression of miR-134 in chemo-sensitive tissue sample as 1,
the expression of miR-134 in chemo-resistant tissue group was
0.6488 ± 0.2028 (P = 0.0098) (Fig. 1B).
To determine the potential clinicopathological implications of
decreased miR-134 expression, we carried out analysis in these
40 ovarian cancer patients including 20 drug resistant tissue sam-
ples and 20 drug sensitive tissue samples combining the qPCR
results and clinical parameters. Correlation between the decreased
miR-134 expression level and, clinicopathological characteristics of
ovarian cancer patients are summarized in Table 1. Statistical anal-
ysis showed that there was no significant association between
miR-134 expression level, and, any of the listed parameters includ-
ing menopausal, grade by two-tiered system (high-grade, low-
grade), FIGO stage and also lymph node metastasis (Table 1)
(P > 0.05).
To evaluate whether the miR-134 level of serous EOC tissue
could be used as potential diagnostic markers for determining
the chemo-resistant feature of ovarian cancer patients, ROC curve
analyses were performed. Level of miR-134 could be a possible
marker for discriminating ovarian cancer patients who are resis-
tant to chemotherapy from patients who are sensitive to
chemotherapy with ROC curve areas of 0.712 (95% CI: 0.550–
0.875, P = 0.021) (Fig. 1C). According to the ROC curve, the
sensitivity and specificity for the prediction of ovarian cancer
chemo-resistance were 60.0% and 85% when the cutoff point to
predict ovarian cancer chemo-resistance was set at 2.471. The
expression of miR-134 in chemo-resistant tissue which showed a
decrease about 35.12% compared with chemo-sensitive tissue
along with the ROC curve result suggest that decreased expression
of miR-134 in ovarian cancer tissues of the patients from the sur-
gery could be detected as a biomarker which showed a medium
accuracy and could be applied as a reference to discriminate
chemo-resistant serous EOC from chemo-sensitive serous EOC.
Fig. 1. Decreased expression of miR-134 in serous EOC chemo-resistant tissues by miRNA microarray, and confirmed by qRT-PCR with the predictive value of the miR-134
expression in ovarian cancer chemoresistance. (A) Differentially expressed miRNAs between chemo-resistant tissue samples, and chemo-sensitive tissue samples detected by
miRNA microarray. SAM (significance analysis of microarrays) was applied to identify the potential differentially expressed miRNAs. In the SAM output sheet, there are three
differentially expressed miRNAs. MiR-210 and miR-1307 were positive genes while miR-134 was negative gene. The criteria for differentially expressed miRNA is |Score
(d)|P 2, and fold changeP2 or 60.5. ‘‘Numerator” means the numerator of the T-statistic, ‘‘Denominator (s + s0)”means the denominator of the T-statistic. (B) Expression of
miR-134 was detected in 20 pairs of ovarian cancer chemo-resistant and chemo-sensitive tissue samples by qPCR. Waterfall plot showing the expression levels of miR-134 in
each of the serous EOC tissue samples which were divided into chemo-sensitive group and chemo-resistant group and sorted from high (left) to low (right). MiR-134
expression was significantly down-regulated in chemo-resistant tissues vs. chemo-sensitive tissues (P = 0.0098). (C) Receiver operating characteristic curve of the miR-134
value of tissue samples from ovarian cancer patients. The area under the curve was 0.712 and it is of great statistical significance compared with our predefined significance
level (P = 0.021). The sensitivity and specificity for the prediction of ovarian cancer chemo-resistance were 60% and 85% when the cutoff point was set at 2.471 (**P < 0.01).
T. Shuang et al. / FEBS Letters 589 (2015) 3154–3164 31573.2. MiR-134 directly targets Pak2 CDS region
To explore the putative target of miR-134, we applied hybrid
PCR [17] method and found Pak2 gene was one of the potential tar-
gets of miR-134 with one putative target site in the CDS region and
the target sequences were highly conserved among different spe-
cies (Fig. 2A). To validate whether Pak2 gene is a direct target of
miR-134, luciferase reporter assay was performed in our study.
We successfully constructed luciferase reporter plasmid containing
the binding site sequences, and, then the corresponding mutation
luciferase reporter plasmid containing a deletion of the miR-134
target site (mutation) was successfully sub-cloned upstream of
the luciferase genes which was clarified by sequencing (shown in
Fig. 2B). The mechanism of miRNA binding to its targets always
need overexpression of miRNA. As miR-134 expression was
decreased in SKOV3-TR30 cells compared with in SKOV3 cells, sowe selected SKOV3-TR30 cells which were co-transfected with
miR-134 mimic and pMIR-Pak2 reporter for luciferase activity
assay. The luciferase activity results showed that co-transfection
of pMIR-Pak2 with miR-134 mimic led to a significant decrease
in luciferase activity compared with co-transfection of pMIR-
Pak2 with miRNA mimic NC (0.6779 ± 0.11083 vs. 1.0792 ±
0.6924, P = 0.01). While in the group of pMIR-Pak2-mutant
reporter and the empty pMIR-reporter, there was no significant
difference between co-transfected with miR-134 mimic and
co-transfected with miRNA mimic NC (Fig. 2C).
3.3. MiR-134 regulates Pak2 expression level at post-transcriptional
level
By applying real-time PCR and western blot we found that there
was no significant difference of Pak2 mRNA expression levels
Table 1
Association of miR-134 expression with the clinicopathological features of serous epithelial ovarian carcinoma, serous epithelial ovarian carcinoma (serous EOC) drug resistant
tissue and serous EOC drug sensitive tissue.
Clinical pathologic
factors
Serous EOC tissue Serous EOC drug resistant tissue Serous EOC drug sensitive tissue
n miR-134
expression
T value P
value
n miR-134
expression
T value P
value
n miR-134
expression
T value P
value
Age (years) 0.0356 0.9801 0.985 0.412 1.059 0.177
Post menopausal (>50) 25 2.522 ± 1.5864 10 3.2158 ± 1.5892 15 3.0562 ± 1.8570
Pre menopausal (650) 15 2.065 ± 1.0081 10 4.2356 ± 1.9856 5 2.8569 ± 1.7458
Two tiered system 0.024 0.981 1.802 0.22 0.469 0.716
Low grade 4 3.893 ± 3.38363 2 1.7865 ± 0.86055 2 5.9985 ± 3.98313
High grade 36 3.863 ± 2.19739 18 3.0757 ± 1.59674 18 4.6496 ± 2.46579
FIGO stage 0.5236 0.5813 1.52 0.185 0.657 0.515
I 3 1.568 ± 0.7909 1 2.356 ± 0 2 3.5221 ± 1.2584
II 8 3.859 ± 1.2588 5 3.6525 ± 1.8902 3 2.9897 ± 1.0984
III 29 4.581 ± 1.5361 14 5.8569 ± 2.7137 15 4.1742 ± 2.1492
Lymph node metastasis 0.6893 0.5526 1.154 0.276 1.041 0.312
Detected 14 2.956 ± 1.2530 8 5.5748 ± 2.9150 6 3.4034 ± 1.4947
Not detected 26 4.409 ± 2.2164 12 6.4081 ± 2.8102 14 3.1236 ± 1.2231
Fig. 2. MiR-134 directly target Pak2 in its CDS region. (A) Putative binding site of Pak2 was found by applying hybrid PCR. And the binding region of miR-134 is localized at
420–427 nt of CDS of Pak2 mRNA. Sequence analysis indicated that miR-134 target sequence at 420–427 nt of CDS of Pak2 mRNA is highly conserved across different species.
(B) Sequencing was used to identify that the PMIR-Pak2 and PMIR-Pak2-mut plasmid were successfully constructed for luciferase reporter assay. (C) Luciferase assay was
applied to confirm the direct interaction of miR-134 with Pak2 binding site sequences. SKOV3-TR30 cells were co-transfected with miR-134 mimic or miRNA mimic NC and
the luciferase reporter constructs (PMIR-Pak2), the mutant (PMIR-Pak2-mut), or PMIR-Report vector. The assays were performed in triplicate (*P < 0.05, ‘‘ns” means the
difference is not significant).
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Pak2 protein was significantly over-expressed in ovarian cancer
paclitaxel resistance cell line SKOV3-TR30 than in its parental cell
line SKOV3. Bar graph shows the ratio of mean densitometry value
of Pak2 protein expression levels in SKOV3-TR30 compared with in
SKOV3 cells. Pak2 expression in SKOV3 was normalized as 1,
expression of Pak2 in SKOV3-TR30 was calculated as
8.2746 ± 0.38828 (P = 0.001) (Fig. 3B). As we discovered miR-134
targets Pak2 gene in its CDS region, we assumed that miR-134 reg-
ulates Pak2 gene expression in post-transcriptional level. In order
to validate this, we used miR-134 mimic for over-expressingmiR-134 expression in SKOV3-TR30 cells (miRNA mimic NC as
negative control) and used miR-134 inhibitor (miRNA inhibitor
NC as negative control) to decrease the expression of miR-134 in
SKOV3 cells. By either over-expressing miR-134 in SKOV3-TR30
cells or down-regulating miR-134 in SKOV3 cells we could fully
confirm the binding effect, so we applied both SKOV3 and
SKOV3-TR30 cells. The qPCR result showed that miR-134 mimic
and miR-134 inhibitor were successfully transfected in SKOV3-
TR30 cells and SKOV3 cells separately (Fig. 3C). Pak2 mRNA levels
were tested and the results suggested that mRNA level was not sig-
nificantly decreased in SKOV3-TR30 cells when transfected with
Fig. 3. miR-134 regulation of Pak2 expression in post-transcriptional level. (A) The difference of Pak2 mRNA expression between SKOV3 and SKOV3-TR3 was not significant.
(B) Bar graph shows the ratio of mean densitometry value of Pak2 protein expression level in SKOV3-TR30 compared with in SKOV3 cells. Expression of Pak2 protein was
significantly increased in SKOV3-TR30 cells compared with in SKOV3 cells (P = 0.001). (C) Effect of miR-134 mimics and inhibitor transfection on modulation of miR-134
expression in SKOV3-TR30 cell lines and SKOV3 cell lines. Left Y axis was shown as log2 of the original. Expression of miR-134 level in SKOV3 cells was normalized as 1. In
SKOV3-TR30 cells miR-134 shown decreased expression (P = 0.0012). The expression of miR-134 was significantly increased in SKOV3-TR30 cells transfected with miR-134
mimic compared with in SKOV3-TR30 cells transfected with miRNA mimic NC (P = 0.008). On the other hand, miR-134 decreased significantly in SKOV3 cells transfected with
miR-134 inhibitor, compared with transfected with miRNA inhibitor NC (P = 0.02). (D) Pak2 mRNA level was not significantly increased in SKOV3-TR30 cells when transfected
with miR-134 mimic compared with miRNA mimic NC. (E). Bar graph shows the ratio of mean densitometry value of Pak2 protein in each cell lines. The protein level of Pak2
down-regulated significantly in SKOV3-TR30 transfected with miR-134 mimic compared with miRNA mimic NC (0.2533 ± 0.04711 vs. 0.8936 ± 0.13234, P = 0.023). (F) Pak2
mRNA level was similar between SKOV3 transfected miR-134 inhibitor and SKOV3 transfected miRNA inhibitor NC. (G) Bar graph shows the ratio of mean densitometry value
of Pak2 protein in each cell lines. The expression of Pak2 protein level increased significantly in SKOV3 cells transfected miR-134 inhibitor compared with transfected with
miRNA inhibitor NC (1.960 ± 0.05581 vs. 0.8875 ± 0.15904, P = 0.012) (G) (*P < 0.05, **P < 0.01).
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Whereas the protein level of Pak2 down-regulated significantly
in SKOV3-TR30 transfected with miR-134 mimic compared with
miRNA mimic NC (0.2533 ± 0.04711 vs. 0.8936 ± 0.13234,
P = 0.023) (Fig. 3E). On the other hand, mRNA level was similar in
SKOV3 transfected miR-134 inhibitor and miRNA inhibitor NC
(Fig. 3F). While the expression of Pak2 protein level increased sig-
nificantly in SKOV3 cells transfected miR-134 inhibitor compared
with transfected with miRNA inhibitor NC (1.960 ± 0.05581 vs.
0.8875 ± 0.15904, P = 0.012) (Fig. 3G).
3.4. MiR-134 enhanced paclitaxel-sensitivity and induces apoptosis in
ovarian cancer SKOV3-TR30 cells via Pak2
To further investigate the effect of miR-134 on cell proliferation
and paclitaxel resistance, we transiently transfected miR-134mimic (miRNA mimic NC) in SKOV3-TR30 cells. Cells were treated
with increasing paclitaxel concentrations, and their inhibition rates
and the paclitaxel IC50 values were determined by CCK-8 cell sur-
vival assays. After treatment with paclitaxel, compared with
SKOV3-TR30-miRNA mimic NC cells, the inhibition rate of
SKOV3-TR30-miR-134 mimic cells increased significantly. When
the concentration was 160nM, the difference was most significant
(58.6237 ± 1.53027 vs. 27.4944 ± 10.27831, P = 0.007) (Fig. 4A).
IC50 value of SKOV3-TR30-miR-134 mimic cells was significantly
lower than the SKOV3-TR30-miRNA mimic NC cells (125.5 ±
21.13 nM vs. 517.5 ± 142.1 nM, P = 0.0371) (Fig. 4B and C). These
results indicate that miR-134 could act as an important factor in
paclitaxel sensitivity in SKOV3-TR30 cells. Since Pak2 is a direct
target of miR-134, we hypothesized that the effect of increased
inhibition rate of miR-134 on SKOV3-TR30 might be achieved via
targeting Pak2. To clarify this, we tested whether RNAi-mediated
Fig. 4. Overexpression of miR-134 and knockdown of Pak2 stimulates paclitaxel sensitivity in SKOV3-TR30 cells. (A) The viability of cells was measured using the CCK-8
assay. Over-expression of miR-134 in SKOV3-TR30 cells increased its inhibition rate after treated with paclitaxel. Each point represents the mean ± SD, n = 3, *P < 0.05,
**P < 0.01. (B and C) Dose–response curves and IC50 values were generated using GraphPad Prism 5.0 (B) Dose–response curves were transformed from chart A (C) IC50 value
of SKOV3-TR30-miR-134 mimic cells was significantly lower than the SKOV3-TR30-miRNAmimic NC cells (125.5 ± 21.13 nM vs. 517.5 ± 142.1 nM, P = 0.0371. Data are shown
as mean ± SD, n = 3, *P < 0.05. (D) The results showed that both siRNA-Pak2-1 and siRNA-Pak2-2 could efficiently suppress the expression of Pak2 and we randomly chose
siRNA-Pak2-1 for further study (***P < 0.001). (E) Inhibition rate of SKOV3-TR30 cells transfected with siRNA-Pak2 also increased significantly compared with treated with
siRNA NC. When the concentration was 160nM, the difference was most significant (77.3707 ± 5.47007 vs. 28.6865 ± 1.43526, ***P < 0.001. (F and G) Dose–response curves
and IC50 values were generated using GraphPad Prism 5.0. (F) Dose–response curves were transformed from chart E. (G) IC50 value was significantly lower than the control
group (72.89 ± 7.575 nM vs. 524.9 ± 71.57 nM, P = 0.0195). Data are shown as mean ± SD, n = 3, *indicates P value < 0.05. (H and I) Effect of miR-134 or Pak2 expression on cell
apoptosis in SKOV3-TR30 cells. Cells were transfected with miR-134 mimic (miRNA mimic NC) or Pak2-siRNA (siRNA NC) as described above. After treated with paclitaxel for
24 h, cells were harvested and then apoptosis was analyzed with an Annexin V-FITC Apoptosis Detection Kit by flow cytometry. Cells were classified as damaged cells
(Annexin V, PI +) shown in Q1 area, late apoptotic cells (Annexin V+, PI +) shown in Q2 area, healthy cells (Annexin V, PI) shown in Q3 area, and early apoptotic cells
(Annexin V+, PI) shown in Q4 area. The ratio of apoptosis among different experimental groups was shown in the bar-chart. Apoptosis ratio was early apoptosis percentage.
(H) Enforced miR-134 expression inSKOV3-TR30 cells increased cell apoptosis after treatment with paclitaxel (15.45 ± 0.66340 vs. 9.25 ± 0.49275, ***P < 0.001). (I) When
SKOV3-TR30 cells were treated with Pak2-siRNA, cell apoptosis also increased which was consistent with that of miR-134 over-expression (20.7400 ± 2.01365 vs.
9.5333 ± 0.56862, P = 0.001).
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TR30 cells. The protein levels of Pak2 decreased significantly after
SKOV3-TR30 treated with both Pak2 siRNA-1 (0.1158 ± 0.02231,
P < 0.001) and Pak2 siRNA-2 (0.1333 ± 0.04711, P < 0.001)
(Fig. 4D). We selected Pak2 siRNA-1 in the following assays. CCK-
8 assay was conducted to determine the effect of Pak2 siRNA on
cell inhibition. The results showed that Pak2 siRNA treatment
caused increased cell inhibition rate in SKOV3-TR30 cells at 48 h.
When the concentration was 160nM, the difference was most sig-
nificant (77.3707 ± 5.47007 vs. 28.6865 ± 1.43526, P = 0.0001)
(Fig. 4E). IC50 value was significantly lower than the control group
(72.89 ± 7.575 nM vs. 524.9 ± 71.57 nM, P = 0.0195) (Fig. 4F and G).
Our study demonstrated that miR-134 by regulating Pak2 expres-
sion might affect paclitaxel sensitivity in ovarian cancer cells.
Anti-apoptosis is one of the reasons for the development of
paclitaxel, and because Pak2 functions in apoptosis signaling, we
hypothesized that miR-134 by regulating Pak2 gene might be
involved in paclitaxel-resistance in SKOV3-TR30 cells. SKOV3-
TR30 cells were transfected with miR-134 mimic (miR-134 mimic
NC) or transfected with siRNA-Pak2-1 (siRNA negative control).
After transfection, cells were exposed to paclitaxel for 24 h. By flow
cytometry analysis, the results showed that elevated expression of
miR-134 in SKOV3-TR30 cells could increase cell apoptosis
(15.45 ± 0.66340 vs. 9.25 ± 0.49275, P < 0.001) (Fig. 4H), and when
Pak2 expression was suppressed, cell apoptosis also increased
(20.7400 ± 2.01365 vs. 9.5333 ± 0.56862, P = 0.001) (Fig. 4I). Then
we employed a ‘‘rescue” experiment by transfecting miR-134
mimic, and Pak2 overexpression plasmid pBI-Pak2 (transfected
with miR-134 mimic along with pBI as inner control) in SKOV3-
TR30 cells. Results of CCK-8 shown that cell inhibition rate
decreased significantly in SKOV3-TR30 cells transfected with
miR-134 mimic along with pBI-Pak2 compared with SKOV3-TR30
cells transfected with miR-134 mimic and along with pBI emptyFig. 5. Over-expression of Pak2 could rescue the effect of miR-134 up-regulation on th
inhibition rate decreased significantly in SKOV3-TR30 cells transfected with miR-134 mim
mimic and along with pBI empty plasmid. When the concentration was 160nM, the differ
C) Dose–response curves and IC50 values were generated using GraphPad Prism 5.0. D
higher than the control group (503.8 ± 58.61 vs. 181.5 ± 20.18, P = 0.0139). Data are show
tested in the above groups. Cells were classified as damaged cells (Annexin V, PI+) show
(Annexin V, PI) shown in Q3 area, and early apoptotic cells (Annexin V+, PI) shown in
the bar-chart. Apoptosis ratio was early apoptosis percentage. Cells transfected with m
transfected with miR-134 mimic and along with pBI empty plasmid (9.2533 ± 0.34530 vplasmid. When the concentration was 160 nM, the difference was
significant (31.8261 ± 6.53498 vs. 48.6924 ± 3.23480, P = 0.016)
(Fig. 5A). IC50 value was significantly higher than the control group
(503.8 ± 58.61 vs. 181.5 ± 20.18, P = 0.0139) (Fig. 5B and C). In the
apoptosis assay, cells transfected with miR-134 mimic along with
pBI-Pak2 displayed decreased apoptosis rate than cells transfected
with miR-134 mimic and along with pBI empty plasmid
(9.2533 ± 0.34530 vs. 20.2000 ± 0.93787, P < 0.001) (Fig. 5D). These
results indicate that Pak2 might be the functional target of miR-
134 in regulating cell survival and apoptosis in SKOV3-TR30 cells.
3.5. MiR-134 by regulating Pak2 might affect the pro-apoptotic Bcl-2
family protein Bad and after that cause suppression of cell death and
apoptosis
As mentioned above pak2 was governed by miR-134, and it
knocked down the expression of Pak2 gene that promoted
increased inhibition rate of SKOV3-TR30 cells and resulted in
significantly increased cell apoptosis. A previous study has
shown that Pak2 phosphorylates Bad at Ser-112 and Ser-136
and inhibits the pro-apoptotic activity by preventing
heterodimerization with Bcl-2, and Bcl-Xl [18]. Additionally,
Jakobi et al. in their study found that Pak2 gene suppressed pro-
grammed cell death of BALB3T3 fibroblasts by phosphorylating
Bad at Ser-112 and Ser-136 [19]. So in our study we researched
if miR-134 inhibiting cell proliferation and promoting cell apop-
tosis by regulating Pak2 gene and after that affect bcl-2 family
member Bad by phosphorylation of Bad at Ser-112 and Ser-
136. We employed a ‘‘rescue” experiment by transfecting miR-
134 mimic, and Pak2 overexpression plasmid pBI-Pak2 in
SKOV3-TR30 cells. The expression of Bad, bad-112, bad-136 were
analyzed by western blot. We found when SKOV3-TR30 cells
were transfected with miR-134mimic, Pak2 expressione sensitivity of SKOV3-TR30 cells to paclitaxel. (A) CCK-8 results shown that cell
ic along with pBI-Pak2 compared with SKOV3-TR30 cells transfected with miR-134
ence was significant (31.8261 ± 6.53498 vs. 48.6924 ± 3.23480, P = 0.016) (A). (B and
ose–response curves were transformed from chart A. IC50 value was significantly
n as mean ± SD, n = 3, *P value < 0.05. (D) Flow cytometry analysis of apoptosis was
n in Q1 area, late apoptotic cells (Annexin V+, PI+) shown in Q2 area, healthy cells
Q4 area. The ratio of apoptosis among different experimental groups was shown in
iR-134 mimic along with pBI-Pak2 displayed decreased apoptosis rate than cells
s. 20.2000 ± 0.93787, ***P < 0.001).
Fig. 6. Analysis of Bad-phosphorylation in SKOV3-TR30 cells and SKOV3 cells. (A) SKOV3-TR30 cells were transfected miR-134 mimic, miRNA mimic NC, miR-134 + pBI-Pak2,
miR-134 + plasmid pBI. (B) SKOV3 cells were treated with the miR-134 inhibitor, miRNA inhibitor NC, miR-134 inhibitor + Pak2 siRNA, miR-134 inhibitor + siRNA NC. Cell
lysates from transfected were analyzed by western blot with an anti-Bad antibody, and Phospho-Bad (Ser112, Ser136) antibody. Bar graph shows the ratio of mean
densitometry value of the tested protein in each group. Results shown are representative of three independent experiments. (*P < 0.05).
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decreased accordingly, while transfection of Pak2 overexpression
plasmid pBI-Pak2 alleviated the reduction of Pak2 gene and
Phospho-Bad (Ser112, Ser136) induced by miR-134 mimic treat-
ment in SKOV3-TR30 cells (Fig. 6A). On the contrary, miR-134
inhibitor, miRNA inhibitor NC, miR-134 inhibitor with Pak2
siRNA, and miR-134 inhibitor with siRNA NC were transfected
in SKOV3 cells. The phosphorylation of endogenous Bad at Ser-
112 and Ser-136 was significantly increased when SKOV3 cells
were treated with miR-134 inhibitor while knocked down the
expression of Pak2 gene recued the trend. Western blot with
the antibody of Bad showed no change in the Bad expression.
These findings confirm the role of miR-134 regulating Pak2 gene
contributes to ovarian cancer cell sensitivity, maybe through Bad
phosphorylation at Ser112 and Ser136 (Fig. 6B).
4. Discussion
Ovarian cancer is most frequently treated with taxane-based
chemotherapy. Although initial treatment is successful for
80–90% of the patients, most responders eventually become resis-
tant to a broad range of chemotherapeutic agents thus chemoresis-
tance is one of the most significant obstacles to the successful
treatment of ovarian cancer [20].
MiR-134 has been studied in hepatocellular carcinoma, head
and neck carcinoma, and glioblastoma where it played a critical
role as a tumor suppressor gene [13–16]. For instance, Kitamura
in their study found that miR-134 through targeting of TGF-b
induced epithelial mesenchymal transformation, and chemoresis-
tance in lung adenocarcinoma cancer cells [16]. However, at the
present expression profile of miR-134 and its possible mechanism
in ovarian cancer chemo-resistance is not studied.In our study, we applied microarray analysis to find an abnor-
mal miRNA expression profile in 4 pairs of serous EOC chemo-
resistant tissues, and chemo-sensitive tissues and found that
miR-134 decreased. We further investigated miR-134 expression
by a qPCR method in 20 cases of serous EOC chemo-sensitive tis-
sues, 20 cases of serous EOC chemo-resistant tissues and found
that miR-134 expression was significantly down-regulated in
chemo-resistant tissues. This indicated a possible participation of
decreased expression of miR-134 on serous EOC chemo resistance.
We found miR-134 expression was not associated with menopau-
sal, tumor differentiation, FIGO stage, and lymph node metastasis
(P > 0.05), while ROC curve implied that miR-134 could be a poten-
tial marker for discriminating serous epithelial ovarian cancer
patients who are resistant to chemotherapy from patients who
are sensitive to chemotherapy. Altogether, these results suggest
that miR-134 may not play a role in the ovarian cancer growth,
and progression but it is specific to chemo-resistance. Hence,
miR-134may be used as a biomarker of chemo-sensitivity for ovar-
ian cancer patients who received the paclitaxel-based chemother-
apy. Then we applied SKOV3-TR30 for further exploring the
decreased expression of miR-134 in ovarian cancer paclitaxel-
resistance. We discovered that restoration of miR-134 increased
the sensitivity of SKOV3-TR30 cells to paclitaxel and enhanced
paclitaxcel-mediated drug apoptosis. These data suggest that
miR-134 may predict chemotherapy response in ovarian cancer.
To reveal the possible mechanism of decreased expression of
miR-134 in ovarian cancer chemoresistance, we applied hybrid
PCR [17] to find the potential target genes for miR-134, and found
Pak2 gene was a potential target of miR-134and the bindingsite
was located in the CDS region of Pak2 mRNA. Then we found
Pak2 protein level was increased in ovarian cancer drug resistant
SKOV3-TR30 cells compared with the parental SKOV3 cells while
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treated with miR-134 mimic (miRNA mimic NC) while SKOV3 cells
were transfected with miR-134 inhibitor (miRNA inhibitor NC). As
the result indicated, we confirmed that Pak2 was negatively regu-
lated by miR-134 at the protein level. Recently many research
studies focused on the CDS region [21–23] of targeted gene tran-
scripts while in our study we found the binding site of miR-134
in the CDS region of Pak2 mRNA.
Pak2 gene caught our attention because it is involved in apop-
tosis, cell cycle arrest, and survival, which could affect the sensitiv-
ity of chemotherapy [24,25]. Several studies have shown that
unlike Pak1 gene, Pak2 gene has a dual function and regulates both
cell survival, and cell death pathways, depending on the milieu.
Activation of full-length PAK2 gene promotes cell survival by phos-
phorylating Bad, and reducing the interaction between Bad and
Bcl-2 or Bcl-x(L), which increases the association between Bad,
and 14-3-3tau, leading to cell survival [19]. In contrast, proteolytic
activation of PAK-2p34 leads to apoptosis [26]. In our study, by
applying Pak2 siRNA, we found SKOV3-TR30 cells showed
increased inhibition rate of proliferation after treated with pacli-
taxel, and we found when the expression of Pak2 decreased,
SKOV3-TR30 cells displayed high percentage of apoptosis rate.
Our result was consistent with the previous study which claimed
that Pak2 was highly expressed in human breast cell lines by
inhibiting cellular apoptosis [27]. To clarify if Pak2 regulated by
miR-134 effects SKOV3-TR30 paclitaxel-induced apoptosis through
Bad family, we applied ‘‘rescue” test by treating SKOV3-TR30 cells
with miR-134 mimic and Pak2 overexpression plasmid, while
transfecting SKOV3 cells with miR-134 inhibitor and Pak2 siRNA,
and then detected the expression of Phospho-Bad (Ser112,
Ser136). The results suggested that when Pak2 gene was regulated
by the miR-134 corresponding change could occur for Bad phos-
phorylation at Ser112 and Ser136.
5. Conclusion
To summarize, in this study we found that miR-134 is signifi-
cantly decreased in serous epithelial ovarian cancer chemo-
resistance tissues compared with chemo-sensitive tissues. We
did not find a correlation between miR-134 level and clinicopatho-
logical parameters of the ovarian cancer patients; however the ROC
curve indicated that miR-134 could be a predictor of ovarian can-
cer chemo-resistance. Furthermore, we confirmed that miR-134
could inhibit proliferation, and promote cell apoptosis whichmight
enhance paclitaxel sensitivity in SKOV3-TR30 cells. By using hybrid
PCR, we found Pak2 gene was a direct target of miR-134, and fur-
ther confirmed miR-134 negatively regulated Pak2 gene expres-
sion at the protein level and down-regulating Pak2 could inhibit
cell proliferation, promot apoptosis in SKOV3-TR30 cells and these
effects might be caused by the overexpression of Pak2 phosphory-
lating Bad into Bad-112, and Bad-136. Decreased expression of
miR-134 might promote paclitaxel-resistance by regulating Pak2
in ovarian cancer cells. Thus miR-134 and its target Pak2 might
be potential targets for therapeutic intervention of ovarian cancer
paclitaxel resistance.
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